- Home
- GEO vs DNTH Comparison
GEO vs DNTH Comparison
Compare GEO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GEO | DNTH |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | GEO | DNTH |
|---|---|---|
| Price | $17.22 | $44.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $41.00 | ★ $68.00 |
| AVG Volume (30 Days) | ★ 1.9M | 780.0K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 515.49 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $2,531,574,000.00 | $3,078,000.00 |
| Revenue This Year | $7.93 | N/A |
| Revenue Next Year | $15.02 | N/A |
| P/E Ratio | $10.14 | ★ N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $14.27 | $13.37 |
| 52 Week High | $36.46 | $45.46 |
Technical Indicators
Market Signals| Indicator | GEO | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 62.45 | 65.78 |
| Support Level | $15.47 | $42.00 |
| Resistance Level | $15.91 | $45.46 |
| Average True Range (ATR) | 0.54 | 2.00 |
| MACD | 0.38 | 0.13 |
| Stochastic Oscillator | 93.62 | 79.49 |
Price Performance
Historical ComparisonAbout GEO Geo Group Inc (The) REIT
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.